Head and Neck Melanoma; Access to Staging and Surgical Treatment
NCT05900102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86000
Last updated 2025-04-04
Summary
Melanoma is a serious type of skin cancer and is the 5th most common cancer in the United Kingdom (UK). It can affect anywhere on the skin including on the head and neck. The cancer often is first noticed as an abnormal mole. Treatment is by removing the cancer with surgery. Early spread of the cancer can be found by testing nearby glands called lymph nodes. This operation is called a sentinel lymph node biopsy (SLNB). If the cancer has spread then new treatments, such as immunotherapy, can be given to help the person live for longer.
The sentinel lymph nodes are usually in the armpits or groin for melanoma on the body, arms or legs. For cancers in the head and neck the sentinel lymph nodes will usually be in the neck. For several reasons SLNB in the neck is not offered in every hospital that manages patients with melanoma. The problem with this is that some patients who could benefit are not offered the new treatments that extend life because it is not known that their cancer has spread.
In this study we aim to gather national data on the management of melanoma of the head and neck including variation in practice between different hospitals. We will use routinely collected anonymous data called 'Hospital Episode Statistics' to look at who is offered SLNB after melanoma of the head or neck, what treatments they have, if their melanoma comes back and how long they survive for.
By doing this, we hope to identify whether SLNB should be made available to everyone diagnosed with melanoma of the head and neck.
Conditions
- Melanoma (Skin)
- Melanoma
Sponsors & Collaborators
-
Hull University Teaching Hospitals NHS Trust
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-01
- Primary Completion
- 2025-01-01
- Completion
- 2025-01-01
Countries
- United Kingdom
Study Locations
More Related Trials
-
Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.
NCT06994208 ·Status: RECRUITING
-
Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
NCT02828202 ·Status: RECRUITING
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550 ·Status: RECRUITING
-
MoleGazer Development Feasibility Study
NCT05015816 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
NCT01245062 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
NCT00942162 ·Status: COMPLETED ·Phase: PHASE2
-
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
NCT07148245 ·Status: RECRUITING
-
A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
NCT01395121 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database
NCT05426239 ·Status: COMPLETED
-
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
NCT04493723 ·Status: RECRUITING
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
NCT04389112 ·Status: UNKNOWN ·Phase: NA
-
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
NCT05402059 ·Status: UNKNOWN
-
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
NCT05510466 ·Status: UNKNOWN
-
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
NCT00040352 ·Status: RECRUITING
-
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
NCT04653038 ·Status: TERMINATED ·Phase: PHASE1
-
Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma
NCT00003747 ·Status: UNKNOWN ·Phase: PHASE1
-
The Role of Melanocyte in Basal Cell Carcinoma
NCT02576769 ·Status: UNKNOWN
-
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
NCT03605771 ·Status: RECRUITING
-
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
NCT06670300 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Impact of Obstructive SAS on Metastatic Potential of Cutaneous Melanoma
NCT02699918 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
NCT02619058 ·Status: UNKNOWN ·Phase: PHASE1
-
The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
NCT05238363 ·Status: UNKNOWN ·Phase: PHASE2
-
Employment and Quality of Life in Patients With Malignant Melanoma
NCT02668887 ·Status: COMPLETED
-
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy
NCT06809491 ·Status: ACTIVE_NOT_RECRUITING